Headlines about EXACT Sciences (NASDAQ:EXAS) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. EXACT Sciences earned a news impact score of 0.22 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 45.9965933255499 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

A number of research analysts have commented on the company. Zacks Investment Research upgraded EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 target price on the stock in a research note on Tuesday, January 16th. BidaskClub upgraded EXACT Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. William Blair reiterated a “buy” rating on shares of EXACT Sciences in a research note on Wednesday, January 10th. Goldman Sachs Group started coverage on EXACT Sciences in a research note on Monday, January 29th. They set a “neutral” rating and a $51.00 price target for the company. Finally, Bank of America upped their price target on EXACT Sciences from $58.00 to $67.00 and gave the stock a “buy” rating in a research note on Wednesday, November 29th. Eight investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. EXACT Sciences presently has a consensus rating of “Buy” and an average target price of $52.84.

EXACT Sciences (NASDAQ:EXAS) traded down $0.28 on Friday, hitting $48.86. The stock had a trading volume of 1,228,373 shares, compared to its average volume of 3,370,000. The company has a market cap of $5,850.00, a P/E ratio of -42.49 and a beta of 0.58. EXACT Sciences has a 52 week low of $19.54 and a 52 week high of $63.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34.

In related news, insider Graham Peter Lidgard sold 45,770 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $58.27, for a total transaction of $2,667,017.90. Following the completion of the transaction, the insider now owns 237,820 shares of the company’s stock, valued at approximately $13,857,771.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP D Scott Coward sold 1,665 shares of the business’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $52.54, for a total value of $87,479.10. Following the transaction, the senior vice president now directly owns 37,558 shares of the company’s stock, valued at approximately $1,973,297.32. The disclosure for this sale can be found here. Insiders have sold a total of 764,182 shares of company stock valued at $40,574,047 in the last three months. 4.00% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “EXACT Sciences (EXAS) Receiving Somewhat Positive Press Coverage, Analysis Finds” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/02/19/exact-sciences-exas-receiving-somewhat-positive-press-coverage-analysis-finds.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.